多发性骨髓瘤免疫治疗的新时代。 - Suppr

Suppr

超能文献

A new era of immune therapy in multiple myeloma.

作者信息

Tai Yu-Tzu, Anderson Kenneth C

机构信息

DANA-FARBER CANCER INSTITUTE.

出版信息

Blood. 2016 Jul 21;128(3):318-9. doi: 10.1182/blood-2016-06-719856.

DOI:10.1182/blood-2016-06-719856

PMID:27445408

Abstract

摘要

相似文献

A new era of immune therapy in multiple myeloma.多发性骨髓瘤免疫治疗的新时代。

Blood. 2016 Jul 21;128(3):318-9. doi: 10.1182/blood-2016-06-719856.

The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies.骨髓瘤的免疫治疗时代：单克隆抗体、疫苗和过继性 T 细胞疗法。

Blood. 2016 Sep 29;128(13):1679-87. doi: 10.1182/blood-2016-05-636357. Epub 2016 Aug 9.

Monoclonal antibodies for treating multiple myeloma - a new era, new safety considerations?用于治疗多发性骨髓瘤的单克隆抗体——新时代，新的安全性考量？

Expert Opin Drug Saf. 2016 Oct;15(10):1295-300. doi: 10.1080/14740338.2016.1201061. Epub 2016 Jul 5.

[Recent development on flow cytometric immunophenotyping study in multiple myeloma --- review].[多发性骨髓瘤流式细胞术免疫表型研究的最新进展——综述]

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Aug;19(4):1083-6.

Thalidomide and lenalidomide in multiple myeloma.沙利度胺和来那度胺在多发性骨髓瘤中的应用

Best Pract Res Clin Haematol. 2006;19(4):769-80. doi: 10.1016/j.beha.2006.06.006.

Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?免疫治疗多发性骨髓瘤：我们现在在哪里？

Curr Hematol Malig Rep. 2019 Feb;14(1):1-10. doi: 10.1007/s11899-019-0492-z.

Advances and practical use of monoclonal antibodies in multiple myeloma therapy.单克隆抗体在多发性骨髓瘤治疗中的进展与实际应用

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):512-520. doi: 10.1182/asheducation-2016.1.512.

Vaccination in Multiple Myeloma: Review of Current Literature.多发性骨髓瘤的疫苗接种：当前文献综述

Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):495-502. doi: 10.1016/j.clml.2016.06.006. Epub 2016 Jun 8.

Myeloma therapy: 25 years forward--immune modulation then and now.

J Clin Oncol. 2008 Oct 10;26(29):4698-700. doi: 10.1200/JCO.2008.18.0109. Epub 2008 Sep 8.

[Immune defects in multiple myeloma].[多发性骨髓瘤中的免疫缺陷]

Nihon Rinsho. 2015 Jan;73(1):52-6.

引用本文的文献

Lymphocytes from B-acute lymphoblastic leukemia patients present differential regulation of the adenosinergic axis depending on risk stratification.B 急性淋巴细胞白血病患者的淋巴细胞根据风险分层呈现出腺苷能轴的差异调节。

Discov Oncol. 2022 Dec 30;13(1):143. doi: 10.1007/s12672-022-00602-1.

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.抗 CD38 抗体治疗复发/难治性多发性骨髓瘤患者：不同的作用机制和最近的临床试验结果。

Ann Hematol. 2022 Oct;101(10):2123-2137. doi: 10.1007/s00277-022-04917-5. Epub 2022 Aug 9.

Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma.PET/CT 联合调节性 B 细胞预测新诊断多发性骨髓瘤患者治疗反应和生存的价值。

Front Immunol. 2021 Aug 19;12:671904. doi: 10.3389/fimmu.2021.671904. eCollection 2021.

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.依沙妥昔单抗通过 Fc 依赖性、非依赖性和直接途径杀死多发性骨髓瘤细胞。

Front Immunol. 2020 Aug 14;11:1771. doi: 10.3389/fimmu.2020.01771. eCollection 2020.

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.靶向 BCMA 的疗法：引领多发性骨髓瘤免疫治疗的新时代

Cancers (Basel). 2020 Jun 5;12(6):1473. doi: 10.3390/cancers12061473.

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.单克隆抗体：一种针对多发性骨髓瘤的新治疗策略。

Antibodies (Basel). 2017 Nov 14;6(4):18. doi: 10.3390/antib6040018.

Should minimal residual disease negativity be the end point of myeloma therapy?微小残留病阴性应成为骨髓瘤治疗的终点吗？

Blood Adv. 2017 Mar 14;1(8):517-521. doi: 10.1182/bloodadvances.2016000117.

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era.在当今治疗达标的时代，基于α干扰素的免疫疗法用于治疗B细胞源性血液系统肿瘤。

Exp Hematol Oncol. 2017 Jul 14;6:20. doi: 10.1186/s40164-017-0081-6. eCollection 2017.

Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu.调节性B细胞与骨髓瘤细胞的相互作用会导致免疫抑制，并促进它们在骨髓微环境中的存活。

Blood Cancer J. 2017 Mar 24;7(3):e547. doi: 10.1038/bcj.2017.24.

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.靶向 CD38 抑制调节性 T 细胞的诱导和功能，减轻多发性骨髓瘤中的免疫抑制。

Clin Cancer Res. 2017 Aug 1;23(15):4290-4300. doi: 10.1158/1078-0432.CCR-16-3192. Epub 2017 Mar 1.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验